Crown Aesthetics向Cavendish Clinics提供屢獲殊榮的SkinPen®精準微針裝置，協助其升級微針療程設備
英國倫敦2024年11月7日 /美通社/ — 隸屬於Crown Laboratories…
阿布達比盧浮宮（Louvre Abu Dhabi）推出全球學者可申請的研究獎學金及資助計劃
此計劃旨在促進藝術歷史、博物館及收藏方面的研究計劃參與者可獨享該館的先進設施現已開放國際學者申請，截…
美通社
Formnext’s South China event to rebrand as Formnext Asia Shenzhen in 2025, reflecting wider reach across Asia
SHENZHEN, China, Oct. 31, 2024 /PRNewswire/ — Following its introduction to the Chinese market in 2021, the Formnext brand has established itself as a trusted name in the country’s additive manufacturing and industrial sectors. Since then, its exhibition in South China has steadily expanded, attracting growing participation from both across
國產PD-L1首度在英國獲批！基石藥業宣布舒格利單抗獲英國藥品和醫療保健用品管理局批准 用於一線治療非小細胞肺癌
這是繼歐盟委員會批准後，舒格利單抗在中國境外獲得的第二項上市許可申請的批准。 此次批准是基於舒格利單…
CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK
This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission. The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, which demonstrated that sugemalimab in combination with chemotherapy significantly prolonged progression-free survival and overall survival in
Kelun-Biotech’s TROP2-ADC SKB264 (sac-TMT) Third NDA Accepted by NMPA, locally advanced or metastatic EGFR-mutant NSCLC
CHENGDU, China, Oct. 31, 2024 /PRNewswire/ — The new drug application based on the positive results from the pivotal phase III OptiTROP-Lung04 study of sacituzumab tirumotecan developed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. was accepted by the Center for Drug Evaluation of the